Publications by authors named "Lin-Xiaoxi Ma"
Background: Although immunotherapy has achieved great progress in advanced triple-negative breast cancer (TNBC), there are still numerous patients who do not benefit from immunotherapy. Therefore, identification of the key molecule that induces immune escape and clarification of its specific mechanism in TNBC are urgently needed.
Methods: In this research, single cell sequencing and bulk sequencing were conducted for biomarker screening.
Article Synopsis
- A phase II trial was conducted to evaluate the efficacy and safety of a new neoadjuvant chemoimmunotherapy regimen combining chemotherapy with the PD-1 antibody toripalimab for early-stage triple-negative breast cancer (TNBC).
- The study included 70 female patients with stage II-III TNBC, who received a combination of standard chemotherapy and immunotherapy, with primary endpoints focusing on total and breast pathological complete response rates.
- Results showed that over half of the participants achieved tumor response, with some experiencing manageable side effects, indicating that this treatment combination is promising and worthy of further research.
Background: Triple-negative breast cancers display heterogeneity in molecular drivers and immune traits. We previously classified triple-negative breast cancers into four subtypes: luminal androgen receptor (LAR), immunomodulatory, basal-like immune-suppressed (BLIS), and mesenchymal-like (MES). Here, we aimed to evaluate the efficacy and safety of subtyping-based therapy in the first-line treatment of triple-negative breast cancer.
View Article and Find Full Text PDF